Skip to main content

Advertisement

SpringerLink
Log in

Treatment of patients with advanced gastric cancer: experience from an Indian tertiary cancer center

  • Original Paper
  • Published:
Medical Oncology Aims and scope Submit manuscript

Abstract

Majority of patients in developing countries diagnosed with gastric cancer have an advanced stage at presentation with overall poor performance status. The aim of the study was to assess outcomes of first- and second-line chemotherapy and determine prognostic factors among patients with advanced gastric cancer (AGC). Using a prospectively maintained database, we identified 144 patients with AGC treated at Tata Memorial Centre between January 2012 and September 2013. Sixteen patients received best supportive care, and 128 patients received palliative chemotherapy. Cox regression was used for multivariate analysis of survival. Of 128 patients, 42(33 %) received Cape-Ox, 22(17.1 %) EOX and 47(36.7 %) DOX while rest received other regimens. PS was 2 in 36 (28 %) patients at presentation, and 97 % of patients had ≥3 sites of metastasis. Forty-eight patients (37.5 %) had signet ring histology. Median follow-up was 9 months. Median progression-free survival/overall survival (OS) was 6/8 months, respectively. Of 93 patients who progressed 39 (41.9 %) patients received second-line chemotherapy. Multivariate analysis for OS showed that PS and use of taxane in first-line setting were significant prognostic factors. Patients who received second-line therapy had longer survival than those who did not (12 vs. 6 months; P = 0.002). The overall outcome of our patients is comparable to the Western reported data despite an advanced disease at presentation.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Ferlay J SI, Ervik M, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray, F.: GLOBOCAN 2012 v10, Cancer Incidence and Mortality Worldwide: IARC CancerBase No 11 [Internet], Lyon, France: International Agency for Research on Cancer; 2013. Available from: http://globocan.iarc.fr, Accessed on 06 July 2014.

  2. Glimelius B, Hoffman K, Haglund U, Nyren O, Sjoden PO. Initial or delayed chemotherapy with best supportive care in advanced gastric cancer. Ann Oncol. 1994;5(2):189–90.

    PubMed  CAS  Google Scholar 

  3. Pyrhonen S, Kuitunen T, Nyandoto P, Kouri M. Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer. Br J Cancer. 1995;71(3):587–91.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  4. Cunningham D, Starling N, Rao S, Iveson T, Nicolson M, Coxon F, Middleton G, Daniel F, Oates J, Norman AR, et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. New England J Med. 2008;358(1):36–46.

    Article  CAS  Google Scholar 

  5. Kang YK, Kang WK, Shin DB, Chen J, Xiong J, Wang J, Lichinitser M, Guan Z, Khasanov R, Zheng L, et al. Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial. Ann Oncol. 2009;20(4):666–73.

    Article  PubMed  Google Scholar 

  6. Ajani JA, Rodriguez W, Bodoky G, Moiseyenko V, Lichinitser M, Gorbunova V, Vynnychenko I, Garin A, Lang I, Falcon S. Multicenter phase III comparison of cisplatin/S-1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: the FLAGS trial. J Clin Oncol. 2010;28(9):1547–53.

    Article  PubMed  CAS  Google Scholar 

  7. Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376(9742):687–97.

    Article  PubMed  CAS  Google Scholar 

  8. Wilson D, Hiller L, Geh JI. Review of second-line chemotherapy for advanced gastric adenocarcinoma. Clin Oncol. 2005;17(2):81–90.

    Article  CAS  Google Scholar 

  9. Ford HE, Marshall A, Bridgewater JA, Janowitz T, Coxon FY, Wadsley J, Mansoor W, Fyfe D, Madhusudan S, Middleton GW, et al. Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial. Lancet Oncol. 2014;15(1):78–86.

    Article  PubMed  CAS  Google Scholar 

  10. Hironaka S, Ueda S, Yasui H, Nishina T, Tsuda M, Tsumura T, Sugimoto N, Shimodaira H, Tokunaga S, Moriwaki T, et al. Randomized, open-label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum: WJOG 4007 trial. J Clin Oncol. 2013;31(35):4438–44.

    Article  PubMed  CAS  Google Scholar 

  11. Shrikhande SV, Barreto SG, Talole SD, Vinchurkar K, Annaiah S, Suradkar K, Mehta S, Goel M. D2 lymphadenectomy is not only safe but necessary in the era of neoadjuvant chemotherapy. World J Surg Oncol. 2013;11:31.

    Article  PubMed  PubMed Central  Google Scholar 

  12. Sharma A. Radhakrishnan V: Gastric cancer in India. Indian journal of medical and paediatric oncology : official journal of Indian Society of Medical & Paediatric Oncology. 2011;32(1):12–6.

    Article  Google Scholar 

  13. Dikshit R, Gupta PC, Ramasundarahettige C, Gajalakshmi V, Aleksandrowicz L, Badwe R, Kumar R, Roy S, Suraweera W, Bray F, et al. Cancer mortality in India: a nationally representative survey. Lancet. 2012;379(9828):1807–16.

    Article  PubMed  Google Scholar 

  14. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63(1):11–30.

    Article  PubMed  Google Scholar 

  15. Crew KD, Neugut AI. Epidemiology of gastric cancer. World J Gastroenterol. 2006;12(3):354–62.

    PubMed  PubMed Central  Google Scholar 

  16. Bonenkamp JJ, Hermans J, Sasako M, van de Velde CJ, Welvaart K, Songun I, Meyer S, Plukker JT, Van Elk P, Obertop H, et al. Extended lymph-node dissection for gastric cancer. New England J Med. 1999;340(12):908–14.

    Article  CAS  Google Scholar 

  17. Yang D, Hendifar A, Lenz C, Togawa K, Lenz F, Lurje G, Pohl A, Winder T, Ning Y, Groshen S, et al. Survival of metastatic gastric cancer: significance of age, sex and race/ethnicity. J Gastrointest Oncol. 2011;2(2):77–84.

    PubMed  CAS  PubMed Central  Google Scholar 

  18. Toneri M, Mitsumoto Y, Shimabukuro M, Sunagawa T, Itagaki T, Iida S, Kondo T, Matsuura K, Okeda J, Dhar DK. Prognosis of patients with gastric carcinoma treated in remote island hospitals in Japan: a multivariable analysis. Anticancer Res. 2006;26(5B):3621–5.

    PubMed  Google Scholar 

  19. Van Cutsem E, Moiseyenko VM, Tjulandin S, Majlis A, Constenla M, Boni C, Rodrigues A, Fodor M, Chao Y, Voznyi E, et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol. 2006;24(31):4991–7.

    Article  PubMed  Google Scholar 

  20. Koizumi W, Narahara H, Hara T, Takagane A, Akiya T, Takagi M, Miyashita K, Nishizaki T, Kobayashi O, Takiyama W, et al. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol. 2008;9(3):215–21.

    Article  PubMed  CAS  Google Scholar 

  21. Davis PA, Sano T. The difference in gastric cancer between Japan, USA and Europe: what are the facts? what are the suggestions? Crit Rev Oncol Hematol. 2001;40(1):77–94.

    Article  PubMed  CAS  Google Scholar 

  22. Wagner AD, Unverzagt S, Grothe W, Kleber G, Grothey A, Haerting J, Fleig WE: Chemotherapy for advanced gastric cancer. The Cochrane database of systematic reviews 2010(3):CD004064.

  23. Onate-Ocana LF, Aiello-Crocifoglio V, Gallardo-Rincon D, Herrera-Goepfert R, Brom-Valladares R, Carrillo JF, Cervera E, Mohar-Betancourt A. Serum albumin as a significant prognostic factor for patients with gastric carcinoma. Ann Surg Oncol. 2007;14(2):381–9.

    Article  PubMed  Google Scholar 

  24. Inal A, Kaplan MA, Kucukoner M, Urakci Z, Guven M, Nas N, Yunce M, Isikdogan A. Prognostic factors in first-line chemotherapy treated metastatic gastric cancer patients: a retrospective study. Asian Pac J Cancer Prev. 2012;13(8):3869–72.

    Article  PubMed  Google Scholar 

  25. Taghavi S, Jayarajan SN, Davey A, Willis AI. Prognostic significance of signet ring gastric cancer. J Clin Oncol. 2012;30(28):3493–8.

    Article  PubMed  PubMed Central  Google Scholar 

  26. Piessen G, Messager M, Leteurtre E, Jean-Pierre T, Mariette C. Signet ring cell histology is an independent predictor of poor prognosis in gastric adenocarcinoma regardless of tumoral clinical presentation. Ann Surg. 2009;250(6):878–87.

    Article  PubMed  Google Scholar 

  27. Lee J, Lim T, Uhm JE, Park KW, Park SH, Lee SC, Park JO, Park YS, Lim HY, Sohn TS, et al. Prognostic model to predict survival following first-line chemotherapy in patients with metastatic gastric adenocarcinoma. Ann Oncol. 2007;18(5):886–91.

    Article  PubMed  CAS  Google Scholar 

  28. Kim JG, Ryoo BY, Park YH, Kim BS, Kim TY, Im YH, Kang YK. Prognostic factors for survival of patients with advanced gastric cancer treated with cisplatin-based chemotherapy. Cancer Chemother Pharmacol. 2008;61(2):301–7.

    Article  PubMed  CAS  Google Scholar 

  29. Shitara K, Muro K, Matsuo K, Ura T, Takahari D, Yokota T, Sawaki A, Kawai H, Ito S, Munakata M, et al. Chemotherapy for patients with advanced gastric cancer with performance status 2. Gastrointestinal cancer research : GCR. 2009;3(6):220–4.

    PubMed  PubMed Central  Google Scholar 

  30. Fuchs CS, Tomasek J, Yong CJ, Dumitru F, Passalacqua R, Goswami C, Safran H, dos Santos LV, Aprile G, Ferry DR, et al. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2014;383(9911):31–9.

    Article  PubMed  CAS  Google Scholar 

  31. Pasini F, Fraccon AP. G DEM: the role of chemotherapy in metastatic gastric cancer. Anticancer Res. 2011;31(10):3543–54.

    PubMed  CAS  Google Scholar 

  32. Shen L, Shan YS, Hu HM, Price TJ, Sirohi B, Yeh KH, Yang YH, Sano T, Yang HK, Zhang X, et al. Management of gastric cancer in Asia: resource-stratified guidelines. Lancet Oncol. 2013;14(12):e535–47.

    Article  PubMed  Google Scholar 

  33. Wagner AD, Grothe W, Haerting J, Kleber G, Grothey A, Fleig WE. Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. J Clin Oncol. 2006;24(18):2903–9.

    Article  PubMed  CAS  Google Scholar 

  34. Einzig AI, Neuberg D, Remick SC, Karp DD, O’Dwyer PJ, Stewart JA, Benson AB 3rd. Phase II trial of docetaxel (Taxotere) in patients with adenocarcinoma of the upper gastrointestinal tract previously untreated with cytotoxic chemotherapy: the Eastern cooperative oncology group (ECOG) results of protocol E1293. Med Oncol. 1996;13(2):87–93.

    Article  PubMed  CAS  Google Scholar 

  35. Sulkes A, Smyth J, Sessa C, Dirix LY, Vermorken JB, Kaye S, Wanders J, Franklin H, LeBail N, Verweij J. Docetaxel (Taxotere) in advanced gastric cancer: results of a phase II clinical trial. EORTC Early clinical trials group. Br J Cancer. 1994;70(2):380–3.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  36. Taguchi T. An early phase II clinical study of RP56976 (docetaxel) in patients with cancer of the gastrointestinal tract. Gan to kagaku ryoho Cancer & chemotherapy. 1994;21(14):2431–7.

    CAS  Google Scholar 

  37. Roth AD, Maibach R, Martinelli G, Fazio N, Aapro MS, Pagani O, Morant R, Borner MM, Herrmann R, Honegger H et al: Docetaxel (Taxotere)-cisplatin (TC): an effective drug combination in gastric carcinoma. Swiss group for clinical cancer research (SAKK), and the European institute of oncology (EIO). Ann Oncol 2000, 11(3):301–306.

  38. Chen XL, Chen XZ, Yang C, Liao YB, Li H, Wang L, Yang K, Li K, Hu JK, Zhang B, et al. Docetaxel, cisplatin and fluorouracil (DCF) regimen compared with non-taxane-containing palliative chemotherapy for gastric carcinoma: a systematic review and meta-analysis. PLoS ONE. 2013;8(4):e60320.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  39. Sekaran A, Kandagaddala RS, Darisetty S, Lakhtakia S, Ayyagari S, Rao GV, Rebala P, Reddy DB, Reddy DN. HER2 expression in gastric cancer in Indian population–an immunohistochemistry and fluorescence in situ hybridization study. Indian J Gastroenterol. 2012;31(3):106–10.

    Article  PubMed  Google Scholar 

  40. Allgayer H, Babic R, Gruetzner KU, Tarabichi A, Schildberg FW, Heiss MM. c-erbB-2 is of independent prognostic relevance in gastric cancer and is associated with the expression of tumor-associated protease systems. J Clin Oncol. 2000;18(11):2201–9.

    PubMed  CAS  Google Scholar 

Download references

Conflicts of interest

None.

Author information

Authors and Affiliations

  1. Department of Medical Oncology, Tata Memorial Centre (TMC), Mumbai, India

    Bhawna Sirohi & Sameer Rastogi

  2. Department of Medical Oncology, Dubai Hospital, Dubai, UAE

    Shaheenah Dawood

  3. Department of Biostatistics, Tata Memorial Centre (TMC), Mumbai, India

    S. Talole

  4. Department of Pathology, Tata Memorial Centre (TMC), Mumbai, India

    Mukta Ramadwar

  5. Department of Radiodiagnosis, Tata Memorial Centre (TMC), Mumbai, India

    Nitin Shetty

  6. Department of Gastrointestinal and Hepato-Pancreato-Biliary Surgical Oncology, Tata Memorial Centre (TMC), Mumbai, India

    Shailesh V. Shrikhande

  7. GI and Breast Cancers, GI Disease Management Group, Tata Memorial Centre (TMC), Parel, Mumbai, 400 012, India

    Bhawna Sirohi

Authors
  1. Bhawna Sirohi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sameer Rastogi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Shaheenah Dawood
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. S. Talole
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Mukta Ramadwar
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Nitin Shetty
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Shailesh V. Shrikhande
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Bhawna Sirohi.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Sirohi, B., Rastogi, S., Dawood, S. et al. Treatment of patients with advanced gastric cancer: experience from an Indian tertiary cancer center. Med Oncol 31, 138 (2014). https://doi.org/10.1007/s12032-014-0138-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s12032-014-0138-x

Keywords

Search

Navigation